In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality. For sepsis, blood purification can remove inflammatory factors in sepsis by filtration or adsorption, so as to achieve the purpose of reducing inflammatory mediators in the body. However, there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different membrane on children with sepsis through a perspective cohort study, so as to provide a corresponding basis for the treatment of children with sepsis blood purification.

Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. In septic shock, dysregulated host responses to pathogens lead to cytokine storms that damage host tissues and organs, further contributing to the development of organ dysfunction and increased mortality.

Blood purification therapy is gradually developed on the basis of renal replacement therapy, and now it is more and more widely used in the field of critical care in children. CVVH can reduce the level of inflammation in the body in different membranes, but the results of reducing inflammatory factors are different, and the outcomes of patients are also different.

Blood purification treatment can reduce inflammatory mediators in sepsis, but there are few prospective randomized controlled studies in children. Therefore, this study intends to compare the efficacy and prognosis of different blood purification membrane in children with sepsis through a perspective cohort study. Provide the corresponding basis for blood purification treatment of the disease.

Inclusion Criteria:

• Meet the 2005 diagnostic criteria for sepsis
• Age 29 days - 18 years old
• Sepsis-induced dysfunction of more than one organ or abnormal tissue perfusion, or septic shock
• Diagnosis < 48 hours

Exclusion Criteria:

• Inability to obtain an informed consent from the subject, family member or an authorized surrogate
• Subject has end-stage renal disease and requires chronic dialysis
• There is clinical support for non-septic shock
• Subject has had chest compressions as part of cardiopulmonary resuscitation this hospitalization without immediate return to communicative state
• Subject has uncontrolled hemorrhage
• Subject has immunodeficiency diseases
• Subject has received chemoradiotherapy or immunosuppressive therapy in the 14 days before enrollment
• HIV infection in association with a last known or suspected CD4 count of <50/mm3
• Subject has sustained extensive third-degree burns within the past 7 days
• Subject has known sensitivity or allergy to heparin or has a history of heparin associated thrombocytopenia
• Subject is currently enrolled in an investigational drug or device trial
• Subject has been previously enrolled in the current trial
• Any other condition, that in the opinion of the investigator, would preclude the subject from being a suitable candidate for enrollment, such as end stage chronic illness with no reasonable expectation of survival to hospital discharge
• Known hypersensitivity to hemofilter
• Subject has received organ transplantation
• Subject is expected to die within 24 hours

children with sepsis requiring blood purification